Suppositories Patents (Class 424/DIG15)
  • Patent number: 6136337
    Abstract: There is provided a composition for rectal administration suitable for curing hemorrhoids or the like by which the concentration of a medicine in the affected tissue is increased and the potency of the medicine is expected to continue. The long acting composition for rectal administration includes an acrylic acid polymer, a vasoconstrictor and a rectal tissue-curing agent.
    Type: Grant
    Filed: July 8, 1998
    Date of Patent: October 24, 2000
    Assignee: Taisho Pharmaceutical Co., Ltd.
    Inventors: Osamu Kondo, Tomoko Fujimori, Shigeo Tanaka, Fumio Urushizaki
  • Patent number: 6110489
    Abstract: Methods for treating male erectile dysfunction are provided. The methods of the present invention comprise the utilization of pharmaceutical compositions to induce erections in males with male erectile dysfunction. The pharmaceutical compositions comprise quinolines and quinolones, as well as derivatives thereof.
    Type: Grant
    Filed: May 1, 1998
    Date of Patent: August 29, 2000
    Inventor: Neal R. Cutler
  • Patent number: 6017554
    Abstract: A stable solution cream, salve, or spray composition containing activated stabilized chlorine dioxide and phosphates, such as disodium hydrogen phosphate, sodium dihydrogen phosphate, trisodium phosphate, and sodium monofluorophosphate, is disclosed for the prevention and treatment of abnormal conditions of the epithelium of bodily orifices. Examples of such abnormal conditions of the epithelium of the rectal, vaginal, urethral, oral, nasal, ocular, and auditory canal orifices include bacterial infections, such as Actinobacillus actinomycetemcomitans and Porphyromonoas gingivalis, and fungal infections, such as Candida, and leukoplakia. The preferred concentration ranges are between about 0.005%-2.0% chlorine dioxide, and between about 0.02%-3.0% phosphate. The phosphate compound retards escape of chlorine dioxide in the pH range of 6.0 to 7.
    Type: Grant
    Filed: September 21, 1998
    Date of Patent: January 25, 2000
    Assignee: Micropure, Inc.
    Inventor: Perry A. Ratcliff
  • Patent number: 6010691
    Abstract: The permeation of a therapeutic agent through the epithelium by topical administration is enhanced by the further topical administration of a stearylamine, transvaccenic acid or a combination of a stearylamine and transvaccenic acid.
    Type: Grant
    Filed: April 26, 1996
    Date of Patent: January 4, 2000
    Assignees: The Regents of the University of California, Cellegy Pharmaceuticals, Inc.
    Inventors: Carl R. Thornfeldt, Peter M. Elias, Stephen Grayson
  • Patent number: 5965151
    Abstract: This bioactive concentrate is an active substance--aqueous solution or lyophilized powder--consisting of anti-hyaluronidase and antiinflammatory mucopolysaccharide polymers and an addition of restitutive and anti-hyaluronidase chondroitinsulphate, which has a pH=4-6 and antihyaluronidase activity. The bioactive concentrate producing method consists in a two--phased treatment of animal--originated connective cartilaginous tissues such as bovine and sheep trachea, umbilical cord, young animal tendons, bowels, testicles or sea organisms, with phenol solution and the solution resulted is concentrated by vacuum evaporation and then defatted; after filtering, the supernatant obtained is treated for deproteinization, the ion excess is removed by passing through ion exchanger column, the alcohol solution is concentrated to remove alcohol until reaching a volume of 70% as against the aqueous solution subject to proteinzation.
    Type: Grant
    Filed: October 3, 1997
    Date of Patent: October 12, 1999
    Assignee: S. C. Tehman S.R.L.
    Inventors: Ioan Manzatu, Dan-Etienne Arizan, Vasile Ionita-Manzatu, Marian Carasava, Maria Panait, Irina-Gabriela Scarlat
  • Patent number: 5935592
    Abstract: A stable solution, cream, salve, or spray composition containing activated chlorine dioxide and phosphates, such as disodium hydrogen phosphate, sodium dihydrogen phosphate, trisodium phosphate, and sodium monofluorophosphate, is disclosed for the treatment of vaginitis and endometriosis by reducing any of Candida, Actinobacillus actinomycetemcomitans, Pseudomonades, and Porphyromonas gingivalis present in the vagina or the uterus. The preferred concentration ranges are in the range of about 0.005% to about 2.0% of chlorine dioxide, and in the range of about 0.02% to about 3.0% of phosphate. The phosphate compound retards escape of chlorine dioxide in the pH range of 6.0 to 7.4, at which pH chlorine dioxide becomes activated and releases sufficient chlorine dioxide to reduce motility and become lethal to the involved micro-organisms.
    Type: Grant
    Filed: May 6, 1998
    Date of Patent: August 10, 1999
    Assignee: Micropure, Inc.
    Inventor: Perry A. Ratcliff
  • Patent number: 5902575
    Abstract: A stable solution, cream, salve, or spray composition containing chlorine dioxide and a phosphate, such as disodium hydrogen phosphate, sodium dihydrogen phosphate, trisodium phosphate, and sodium monofluorophosphate, is disclosed for the prevention and treatment of abnormal conditions of the epithelium of bodily orifices. Examples of such abnormal conditions of the epithelium of the rectal, vaginal, urethral, oral, nasal, ocular, and auditory canal orifices brought about by any of leukoplakia, hairy leukoplakia, vaginitis, endometriosis, Candida Albicans, Actinobacillus actinomycetemcomitans, Porphyromonas gingivalis, Pseudomonades, Candida species, and leukoplakia vulvae. The preferred concentration ranges are between about 0.005%-2.0% chlorine dioxide, and between about 0.02%-3.0% phosphate. The phosphate compound retards escape of chlorine dioxide in the pH range of 6.0 to 7.
    Type: Grant
    Filed: April 27, 1998
    Date of Patent: May 11, 1999
    Assignee: Micropure, Inc.
    Inventor: Perry A. Ratcliff
  • Patent number: 5885565
    Abstract: A method for enhancing penetration of a therapeutic or prophylactic agent in a host in need of the topical administration thereof which comprises applying to the epithelium of the host, an effective amount of one or more penetration enhancing epithelial sterols and the therapeutic or prophylactic agent.
    Type: Grant
    Filed: April 26, 1996
    Date of Patent: March 23, 1999
    Assignees: Cellegy Pharmaceuticals Inc., The Regents of the University of California
    Inventors: Peter M. Elias, Stephen Grayson, Carl R. Thornfeldt
  • Patent number: 5863553
    Abstract: The invention relates to an intravaginally-dissolvable contraceptive suppository, a method of using said suppository, and an improved method of manufacturing said birth control device. The suppositories of the invention, which comprise a lyophilized foam and a contraceptive, have a dissolution time of at least about 2 hours, and up to about 24 hours, and provide superior protection against pregnancy.
    Type: Grant
    Filed: March 7, 1997
    Date of Patent: January 26, 1999
    Assignee: McNeil-PPC, Inc.
    Inventors: Peter Britton, Patricia Flanagan, William P. Hart, Deborah Linkin
  • Patent number: 5834003
    Abstract: A method for oxidatively consuming volatile sulfur compounds selected from the group consisting of dimethylsulfide, hydrogen sulfide, and methylmercaptan at the epithelial barrier of the rectal, vaginal, urethral, oral, nasal, ocular, and auditory canal orifices to maintain the epithelial barrier and reduce penetration of any of Candida, Actinobacillus actinomycetumcomitans, Pseudomonades, and Porphyromonas gingivalis, said method comprising the step of applying to the orifices a composition comprising a topical preparation selected from the group consisting of liquid solutions, suspensions, semi-solids, salves, creams, and suppositories, wherein the topical preparation contains chlorine dioxide in a concentration in the range of about 0.005% to about 2.0% and a phosphate compound selected from the group consisting of disodium hydrogen phosphate, sodium dihydrogen phosphate, trisodiuit phosphate, or sodium monofluorophosphate in a concentration in the range of about 0.02% to about 3.
    Type: Grant
    Filed: April 2, 1997
    Date of Patent: November 10, 1998
    Assignee: Micropure, Inc.
    Inventor: Perry A. Ratcliff
  • Patent number: 5811115
    Abstract: A stable solution, cream, salve, or spray composition containing chlorine dioxide and phosphates, such as disodium hydrogen phosphate, sodium dihydrogen phosphate, trisodium phosphate, and sodium monofluorophosphate, is disclosed for the prevention and treatment of abnormal conditions of the epithelium of bodily orifices. Examples of such abnormal conditions of the epithelium of the rectal, vaginal, urethral, oral, nasal, ocular, and auditory canal orifices include bacterial infections, such as Actinobacillus actinomycetemcomitans and Porphyromonas gingivalis, and fungal infections, such as Candida, and leukoplakia. The preferred concentration ranges are in the range of about 0.005% to about 2.0% chlorine dioxide, and in the range of about 0.02% to about 3.0% phosphate. The phosphate compound retards escape of chlorine dioxide in the pH range of about 6.0 to about 7.
    Type: Grant
    Filed: April 2, 1997
    Date of Patent: September 22, 1998
    Assignee: Micropure, Inc.
    Inventor: Perry A. Ratcliff
  • Patent number: 5747059
    Abstract: The present invention provides novel uses of compounds of general formula I: ##STR1## wherein R.sup.1, R.sup.4 and R.sup.5 are individually hydrogen, hydroxy, halogen, trifluoromethyl, lower alkyl, lower alkoxy or (tertiary amino)(lower alkoxy); and R.sup.2 and R.sup.3 are individually hydrogen or lower alkyl, or as a pharmaceutically acceptable salt thereof in combination with a pharmaceutically acceptable carrier for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of atrophy of skin and/or mucous membranes.
    Type: Grant
    Filed: July 11, 1996
    Date of Patent: May 5, 1998
    Assignee: Novo Nordisk A/S
    Inventors: Niels Korsgaard, James Robertson Piggott, Virender Mohan Labroo, Steven Bain
  • Patent number: 5733568
    Abstract: Micro-encapsulated lactobacilli bacteria are orally administered to mammals, including humans, to treat or prevent antibiotic associated or other chronic or acute diarrhea. Micro-encapsulated lactobacilli bacteria are topically administered to the skin to treat or prevent recurrent skin infections, and are administered intra-vaginally to treat or prevent vaginal yeast infections.
    Type: Grant
    Filed: June 2, 1995
    Date of Patent: March 31, 1998
    Assignee: Lafor Laboratories Limited
    Inventor: Larry C. Ford
  • Patent number: 5674505
    Abstract: Vitamin B12 is used to stimulate heme oxygenase production. In turn, levels of the molecules 12(R)-HETE and 12(R)-DIHETE, which are arachidonic acid derivatives, are reduced. Various topical formulations containing vitamin B12, but no other vitamins, are described.
    Type: Grant
    Filed: August 2, 1994
    Date of Patent: October 7, 1997
    Assignee: Hemogen, Inc.
    Inventors: Richard D. Levere, Nadar G. Abraham, Michal L. Schwartzman, Michael W. Dunn
  • Patent number: 5648101
    Abstract: A method of delivering NO gas to a desired situs on or in the body of a sentient animal, e.g. humans, comprising combining and causing to react a soluble reducing salt, preferably ferrous sulfate, and a nitrite, preferably sodium nitrite, as reactants in the presence of moisture in situ at or adjacent such situs. Means for such delivery include compositions such as tablets, capsules, ointments, creams, lotions, and sprays containing mixtures of particles or granules of the two reactants, and transdermal patches and osmotic pumps for combining solutions of reactant or reactants in situ.
    Type: Grant
    Filed: November 14, 1994
    Date of Patent: July 15, 1997
    Inventor: Rashad Tawashi
  • Patent number: 5648377
    Abstract: The present invention relates to novel formulations and combinations of lipophilic and hydrophilic antioxidants and the use thereof in the therapeutic, foodstuff, dietetic, and cosmetic fields. These formulations are based on the use of carotenoids, procarotenoids and derivatives thereof with polyphenols of catechic structures. Said formulations, containing a lipophilic antioxidant and an hydrophilic one, can be used in the prevention of physiopatological conditions related at least partially to an over-production of free radicals, particularly aging, atherosclerosis and cancer.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: July 15, 1997
    Assignee: Indena S.p.A.
    Inventors: Ezio Bombardelli, Paolo Morazzoni
  • Patent number: 5629012
    Abstract: Suppositories, produced by a process in which a suppository basic mass is produced containing (a) 50-75% of 5-aminosalicylic acid as an active ingredient, (b) 2-5% talc, magnesium stearate and/or polyvinyl pyrrolidone and (c) 20-48% by weight of a polyethylene glycol having an average molecular weight of at least 4000, and the produced mass is compressed to suppositories in a tabletting machine.
    Type: Grant
    Filed: May 26, 1995
    Date of Patent: May 13, 1997
    Assignee: Farmaceutisk Laboratorium Ferring A/S
    Inventor: S.o slashed.ren Halskov
  • Patent number: 5618550
    Abstract: A stable solution, cream, salve, or spray composition containing activated stabilized chlorine dioxide and phosphates, such as disodium hydrogen phosphate, sodium dihydrogen phosphate, trisodium phosphate, and sodium monofluorophosphate, is disclosed for the prevention and treatment of abnormal conditions of the epithelium of bodily orifices. Examples of such abnormal conditions of the epithelium of the rectal, vaginal, urethral, oral, nasal, ocular, and auditory canal orifices include bacterial infections, such as Actinobacillus actinomycetemcomitans and Porphyromonas gingivalis, and fungal infections, such as Candida, and leukoplakia. The preferred concentration ranges are between about 0.005%-2.0% chlorine dioxide, and between about 0.02%-3.0% phosphate. The phosphate compound retards escape of chlorine dioxide in the pH range of 6.0 to 7.
    Type: Grant
    Filed: May 19, 1995
    Date of Patent: April 8, 1997
    Assignee: RBR Holdings
    Inventor: Perry A. Ratcliff
  • Patent number: 5614209
    Abstract: Micro-encapsulated lactobacilli bacteria are orally administered to mammals, including humans, to treat or prevent antibiotic associated or other chronic or acute diarrhea. Micro-encapsulated lactobacilli bacteria are topically administered to the skin to treat or prevent recurrent skin infections, and are administered intra-vaginally to treat or prevent vaginal yeast infections.
    Type: Grant
    Filed: March 13, 1996
    Date of Patent: March 25, 1997
    Assignee: Lafor Laboratories Limited
    Inventor: Larry C. Ford
  • Patent number: 5602180
    Abstract: A method of administering EDTA complexes includes steps of forming a suppository containing an EDTA complex and controlled-release agents which release the EDTA complex over a period of about three to four hours after placement, and then administering the suppository to a patient in lieu of an intravenous drip.
    Type: Grant
    Filed: March 31, 1995
    Date of Patent: February 11, 1997
    Assignee: World Health Group
    Inventor: Ronald Bennett
  • Patent number: 5538728
    Abstract: A complex material of a hydrophilic polymer-silicate mineral comprising a carboxyl group containing hydrophilic polymer and a water swellable silicate mineral, and having a new absorption spectrum not existing in both starting materials in the IR-ray absorption spectrum within the range of 1000 to 1300 cm.sup.-1, and pharmaceutical and cosmetic compositions comprising same.
    Type: Grant
    Filed: April 14, 1993
    Date of Patent: July 23, 1996
    Assignee: Shiseido Company, Ltd.
    Inventors: Toshio Yanaki, Tadahito Takahashi, Yoko Nagasawa, Michihiro Yamaguchi
  • Patent number: 5518730
    Abstract: Biodegradable controlled release delivery systems using melt-spun biodegradable polymers as carriers for bio-effecting agents such as pharmaceutical actives are disclosed. Oral dosage forms as well as implants are described.
    Type: Grant
    Filed: June 3, 1992
    Date of Patent: May 21, 1996
    Assignee: Fuisz Technologies Ltd.
    Inventor: Richard C. Fuisz
  • Patent number: 5516526
    Abstract: This invention relates to a method of protection from and treatment of neurological damage in mammals by administration of dimethylsulfoxide (DMSO) in combination with fructose 1,6-diphosphate (FDP). The effects of administration of the drugs together, either as two separate compositions or in combination, results in synergistic action that greatly improves protection from morbidity in animals (including humans) who have suffered injury to the brain.
    Type: Grant
    Filed: March 22, 1995
    Date of Patent: May 14, 1996
    Inventor: Jack da la Torre
  • Patent number: 5508037
    Abstract: Suppository formulations having long-term stability and containing readily bioavailable .DELTA..sup.9 -THC derivatives.
    Type: Grant
    Filed: February 2, 1995
    Date of Patent: April 16, 1996
    Assignee: The University of Mississippi
    Inventor: Mahmoud A. ElSohly
  • Patent number: 5500221
    Abstract: The present invention relates to a sustained-release suppository preparation characterized by comprising an acidic drug or a salt thereof which can be absorbed by rectal administration and an acidic compound or a pH buffering agent. The sustained-release suppository preparation of the present invention exhibits no rapid increase in blood concentration immediately after the administration and maintains its action for a long period of time. Thus, it is safer and exhibits a better therapeutic effect.
    Type: Grant
    Filed: March 18, 1994
    Date of Patent: March 19, 1996
    Assignee: SS Pharmaceutical Co., Ltd.
    Inventors: Masami Murata, Harumi Kishi, Takashi Narui, Shuichi Kasai, Akira Iwasa
  • Patent number: 5489435
    Abstract: A stable solution, cream, salve, or spray composition containing activated stabilized chlorine dioxide and phosphates, such as disodium hydrogen phosphate, sodium dihydrogen phosphate, trisodium phosphate, and sodium monofluorophosphate, is disclosed for the prevention and treatment of abnormal conditions of the epithelium of bodily orifices. Examples of such abnormal conditions of the epithelium of the rectal, vaginal, urethral, oral, nasal, ocular, and auditory canal orifices include bacterial infections, such as Actinobacillus actinomycetemcomitans and Porphyromonas gingivalis, and fungal infections, such as Candida, and leukoplakia. The preferred concentration ranges are between about 0.005%-2.0% chlorine dioxide, and between about 0.02%-3.0% phosphate. The phosphate compound retards escape of chlorine dioxide in the pH range of 6.0 to 7.
    Type: Grant
    Filed: July 6, 1993
    Date of Patent: February 6, 1996
    Inventor: Perry A. Ratcliff
  • Patent number: 5489577
    Abstract: Disclosed is a semi-solid pharmaceutical agent containing a stabilized proteinaceous bioactive substance prepared by successively mixing an oligosaccharide and an aqueous solution of a proteinaceous bioactive substance, and kneading the resultant solids with an oil or fat base. The pharmaceutical handles with ease because it is readily administered to the body through percutaneous and permucosal route which are safer and less in pain administration routes than other conventional administrations.
    Type: Grant
    Filed: June 28, 1994
    Date of Patent: February 6, 1996
    Assignee: Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo
    Inventors: Masao Ikeda, Tomoki Tatefuji, Hiroshi Yamauchi
  • Patent number: 5482973
    Abstract: A suppository comprising pranoprofen is disclosed. The suppository has analgesic or anti-inflammatory effects. Since pranoprofen is administered away from gastrointestinal tracts, application of the suppository is not accompanied by side effects such as peptic ulcer, bleeding in constipation, and diarrhea. It is particularly suitable for patients with disorders in digestive organs and infant patients. Pranoprofen is released constantly over a extended period of time.
    Type: Grant
    Filed: October 15, 1993
    Date of Patent: January 9, 1996
    Assignee: Dojin Iyaku-Kako Co., Ltd.
    Inventors: Yoichi Sawayanagi, Yutaka Kawamura
  • Patent number: 5466455
    Abstract: Processes for polyphase fluid extraction of concentrated, active therapeutic components from parts of selected medicinal plants which have been identified chemotaxonomically are described. The resulting products-by-processes are defined as Concentrated Fluid Therapeutic Extracts, CFTE, of the selected plant types, where T represents a specific herbal plant family such as Symphytum, SYM, Taxus, TAX, Panax, PAN or Aloe, ALO. The process disclosed for CFTE preparation includes multiple/sequential stages of diffusional transfer of bioactive constituents from plant tissue into liquid and/or vapor extraction phases under contact conditions of forced convection at controlled temperature and pressure. Therapeutic formulations based on CFTE including emulsions, aerosols, liposomes and controlled-release devices are presented. Treatment methods for a variety of mammalian diseases and conditions and complications of specific diseases are described.
    Type: Grant
    Filed: September 15, 1993
    Date of Patent: November 14, 1995
    Inventors: Miles C. Huffstutler, Jr., Gary M. Steuart
  • Patent number: 5466461
    Abstract: New polysaccharide esters are disclosed, and more precisely esters of acidic polysaccharides chosen from the group formed by carboxymethylcellulose, carboxymethyl starch and carboxymethylchitin. These new esters and some esters of the type already known are useful as medicaments, for the manufacture of pharmaceutical and cosmetic preparations, in the field of biodegradable plastic materials and, therefore, for the manufacture of medical, surgical and sanitary articles, as well as numerous other industrial sectors in the place of acidic polysaccharides now in common use.
    Type: Grant
    Filed: April 2, 1992
    Date of Patent: November 14, 1995
    Assignee: Fidia, S.p.A.
    Inventors: Francesco della Valle, Aurelio Romeo
  • Patent number: 5466463
    Abstract: A vaginal suppository or other type of vaginal pessary such as cream, foam or ointment, which contains as its active ingredients at least one pharmaceutically acceptable, topically safe antimicrobial agent, such as an agent selected from the group of benzalkonium chloride, cetylpyridinium chloride, chlorhexidine gluconate and povidone iodine, imidiazolidinyl urea and diazolidinyl urea and a viable colony of micro-encapsulated lactobacilli bacteria. The viable lactobacilli are included in the suppository in micro encapsulated form, which protects the bacteria during storage of the suppository from the action of the bacteriocidal agent. When exposed to the vaginal milieu the micro encapsulation breaks down sufficiently to release the lactobacili bacteria. The lactobacilli bacteria serve to maintain or re-establish a healthy lactobacilli based flora on the vaginal wall, and excrete hydrogen peroxide and other bactericidins which suppress abnormal flora conditions that promote infections.
    Type: Grant
    Filed: September 7, 1994
    Date of Patent: November 14, 1995
    Assignee: Lafor Laboratories Limited
    Inventor: Larry C. Ford
  • Patent number: 5462740
    Abstract: This invention provides a rectally administered composition for inhibiting epileptic seizure and to its methods of use. The composition contains, in a suitable solvent, an anti-epileptic agent for inhibiting epileptic seizure, a buffer for maintaining pH, and a thickener for imparting a viscosity to the composition effective for rectal administration by injection to a patient in epileptic seizure.
    Type: Grant
    Filed: September 17, 1993
    Date of Patent: October 31, 1995
    Assignee: Athena Neurosciences, Inc.
    Inventors: Kenneth L. Evenstad, Victoria A. O'Neill, Thomas R. Gorham
  • Patent number: 5440031
    Abstract: The invention relates to partially novel metal complexes, salts and double salts of 1,4,10,13-tetraoxa-7,16-diazacyclooctadecane compounds of the formula (I), ##STR1## wherein Q.sup.1 and Q.sup.2 mean hydrogen or a group of the formula (III), ##STR2## in the groups of the formula (III) the R subtituents independently represent hydrogen, a C.sub.1-5 straight or branched chain alkyl group, a C.sub.2-5 straight or branched chain alkenyl group, phenyl or phenyl-C.sub.1-5 alkyl group, the two latter ones optionally being substituted on their aromatic part by one or more halogen(s), C.sub.1-5 alkyl, C.sub.1-5 alkoxy, cyano or nitro group(s), with the proviso that at least one of Q.sup.1 and Q.sup.
    Type: Grant
    Filed: August 6, 1993
    Date of Patent: August 8, 1995
    Assignees: Orszagos "Frederic Joliot-Curie" Sugar-biologiai es Sugaregeszsegugyi Kutato Intezet, Kossuth Lajos Tudomanyegyetem
    Inventors: Laszlo Varga, Laszlo B. Sztanyik, Bela Kanyar, Odon Kiraly, Erno Brucher, Jozsef Emri, Bela Gyori, Zoltan Kovacs
  • Patent number: 5422117
    Abstract: The invention provides a multiphase pharmaceutical composition for combatting skin and anorectal conditions requiring medication comprising at least one phase containing one or more medicaments for combatting said disease and at least one porous phase containing a silicone oil absorbed therein and adapted for release, preferably delayed release, of the silicone oil whereby application of said composition at a region affected by said skin or anorectal condition deposits said medicament or medicaments thereon and a layer of silicone oil is formed thereover thus protecting the medicaments from erosion by aqueous media.
    Type: Grant
    Filed: December 18, 1992
    Date of Patent: June 6, 1995
    Assignee: EDKO Trading and Representation Company Ltd.
    Inventors: Oswald Morton, Koral Embil
  • Patent number: 5389375
    Abstract: Suppository formulations having long-term stability and containing readily bioavailable .DELTA..sup.9 -THC derivatives.
    Type: Grant
    Filed: May 21, 1993
    Date of Patent: February 14, 1995
    Assignee: University of Mississippi
    Inventor: Mahmoud A. ElSohly
  • Patent number: 5378470
    Abstract: Described are dry pharmaceutical preparations or clysters designed for rectal administration, which contain an active ingredient or mixture of active ingredients plus additives, and which are only reconstituted immediately before use by the addition of water, the volume of which can be selected to suit the particular patient. Such preparations are preferably marketed in graduated clyster flasks allowing the contents to be diluted with an amount of water appropriate to a particular patient.
    Type: Grant
    Filed: December 20, 1993
    Date of Patent: January 3, 1995
    Assignee: Henning Berlin GmbH
    Inventor: Wolfgang Lahr
  • Patent number: 5364879
    Abstract: The present invention provides a method of medical treatment for a medical condition in a mammal. In this method, a pharmacologically effective amount for treatment of the condition of a trioxolane or a diperoxide of a non-terpene unsaturated hydrocarbon is applied to the mammal. The invention also provides methods of modulating the immune system in a mammal, of treating inflammation of a tissue in a mammal, and of treating bacterial, fungal, protozoal and viral infections in a mammal.
    Type: Grant
    Filed: February 14, 1994
    Date of Patent: November 15, 1994
    Assignee: Cliveden Ltd.
    Inventor: Stephen Herman
  • Patent number: 5360612
    Abstract: This invention relates to pharmaceutical compositions for rectal administration containing semi-synthetic glycerides produced by interesterification, and, as the active ingredient, triazole derivatives of the formula ##STR1## wherein R.sup.1 is phenyl optionally sustituted with from one to three substituents independently selected from the group consisting of F, Cl, Br, I, CF.sub.3,(C.sub.1 -C.sub.4)alkyl, (C.sub.1 -C.sub.4)alkoxy, and 5-chloropyrid-2-yl; X is OH, F, Cl or Br; R.sub.2 is H.sub.2, CH.sub.3 or F; and R.sub.3 is H or F.
    Type: Grant
    Filed: October 13, 1992
    Date of Patent: November 1, 1994
    Assignee: Pfizer Inc.
    Inventors: Walter F. Fries, Gunther F. D. Pfaff, Jorg C. Pfitzner, Gerhard Simon
  • Patent number: 5354558
    Abstract: The invention relates to an intravaginally-dissolvable contraceptive suppository, a method of using said suppository, and an improved method of manufacturing said birth control device. The suppositories of the invention, which comprise a lyophilized foam and a contraceptive, have a dissolution time of at least about 2 hours, and up to about 24 hours, and provide superior protection against pregnancy.
    Type: Grant
    Filed: September 10, 1992
    Date of Patent: October 11, 1994
    Assignee: McNeil-PCC, Inc.
    Inventors: Peter Britton, Patricia Flanagan, William P. Hart, Deborah Linkin
  • Patent number: 5330756
    Abstract: Processes for polyphase fluid extraction of concentrated, active therapeutic components from parts of plants identified taxonomically as Symphytum, Taxus and Aloe species are described. The resulting products-by-processes are defined as Concentrated Fluid Plant Extracts (CFPE) of the respective plant types, where P can be S, T or A. The preparation process for CFPE includes multiple/sequential stages of diffusional transfer of the active constituents into liquid and/or vapor extraction phases under contact conditions of forced convection at controlled temperature and pressure. Therapeutic formulations based on CFPE including emulsions, aerosols, liposomes and controlled-release devices are presented. Treatment methods for a variety of skin conditions and complications of specific diseases are indicated.
    Type: Grant
    Filed: November 24, 1992
    Date of Patent: July 19, 1994
    Inventors: Gary M. Steuart, M. Conrad Huffstutler, Jr.
  • Patent number: 5281711
    Abstract: The compound (S)-1-[(10-chloro-6,7-dihydro-4-oxo-3-phenyl-4H-benzo[a]quino-lizin-1-yl)c arbonyl]-3-ethoxypyrrolidine of the formula ##STR1## which has valuable pharmacological properties, is described. In particular, the compound of formula I has a non-sedating, hypnotic, that is, sleep-promoting, activity and can accordingly be used for the treatment of sleep disorders.
    Type: Grant
    Filed: January 6, 1992
    Date of Patent: January 25, 1994
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Richard R. Scherschlicht, Ulrich Widmer
  • Patent number: 5240700
    Abstract: A composition for inhibiting the degeneration of cells including liver cells by drugs and relieving the toxicity of drugs to internal organs including the liver contains as an essential component a 3-oxygermylpropionic acid polymer which is represented by:[(O.sub.1/2).sub.3 GeCH.sub.2 CH.sub.2 COOH].sub.nwherein n is an integer of at least 1, takes the form of a white acicular crystal and has a melting point of about 230.degree. C. at which it decomposes or coagulates. The present composition may be used with a carrier hydroxypropylcellulose in an amount of 0.005 to 50% by weight relative to 0.005 to 5% by weight of the 3-oxygermylpropionic acid polymer.
    Type: Grant
    Filed: May 7, 1992
    Date of Patent: August 31, 1993
    Assignee: Sanwa Kagaku Kenkyusho Co., Ltd.
    Inventors: Kiichi Sawai, Masayasu Kurono, Kazumasa Nakano, Kyoichi Asano, Takahiko Mitani, Naohisa Ninomiya, Bunkichi Kato
  • Patent number: 5231112
    Abstract: Methods and compositions are described for the preparation of bioactive agents entrapped in lipid vesicles the bilayers of which comprise a salt form of an organic acid derivative of a sterol, such as the tris-salt form of a sterol hemisuccinate, and to bompositions comprising a mixture of tris(hydroxymethyl)aminomethane salt of cholesteryl hemisuccinate with either an antifungal compound or a peptide. These compositions have various applications in vivo.
    Type: Grant
    Filed: October 23, 1989
    Date of Patent: July 27, 1993
    Assignee: The Liposome Company, Inc.
    Inventors: Andrew S. Janoff, Mircea C. Popescu, Alan L. Weiner, Lois E. Bolcsak, Paul A. Tremblay, Christine E. Swenson
  • Patent number: 5215758
    Abstract: The controlled release of therapeutically active agents is achieved from a controlled release matrix of sodium alginate and a calcium salt. When the composition is to be administered rectally, the matrix is combined with a therapeutically active agent and a suitable suppository base. When the composition is to be administered orally, the matrix further includes a higher aliphatic alcohol.
    Type: Grant
    Filed: September 11, 1991
    Date of Patent: June 1, 1993
    Assignee: Euroceltique, S.A.
    Inventor: Thinnayam N. Krishnamurthy
  • Patent number: 5206008
    Abstract: The present invention provides an improved means for regulating the immune response, for ameliorating effects of stress, and for avoiding untoward effects of chemotherapy or exposure to irradiation by administration of androstenediol (AED) and androstenetriol (AET). The improved means of regulating immune response can be utilized in treating infectious diseases and immune diseases such as diabetes and chronic fatigue syndrome, both diseases now considered to be immune response related syndromes.
    Type: Grant
    Filed: August 2, 1991
    Date of Patent: April 27, 1993
    Assignee: Virginia Commonwealth University
    Inventor: Roger Loria
  • Patent number: 5192802
    Abstract: Bioadhesive pharmaceutical carrier consisting essentially of a polymer blend of sodium carboxymethyl cellulose and xanthan gum or sodium alginate. The invention also provides for a method of control releasing a pharmaceutical active comprising incorporating an active into the bioadhesive pharmaceutical carrier. The invention is particularly adaptable for oral use and teething gels.
    Type: Grant
    Filed: September 25, 1991
    Date of Patent: March 9, 1993
    Assignee: McNeil-PPC, Inc.
    Inventor: William F. Rencher
  • Patent number: 5167963
    Abstract: 8,10-Dideazatetrahydrofolic acid derivatives of the formula: ##STR1## where R.sub.1 and R.sub.2 are selected from hydrogen and alkyl having from one to about eight carbon atoms and the carboxylates and acid addition salts thereof, showing strong inhibition of L1210 murine leukemia cells in culture, modest inhibition of glycinamide ribotide transformylase and aminoimidazole carboxamide ribotide transferase, and insignificant inhibition of dihydrofolate reductase and thymidylate synthase enzymes.
    Type: Grant
    Filed: July 27, 1990
    Date of Patent: December 1, 1992
    Assignees: SRI International, Sloan-Kettering Institute for Cancer Research
    Inventors: Joseph I. DeGraw, William T. Colwell, Francis M. Sirotnak
  • Patent number: 5130137
    Abstract: This invention is directed to a delivery system and a method useful for the treatment of benign ovarian secretory disorders in female mammals by administering an LHRH composition. The method comprises administering during the entire follicular phase of the menstrual cycle, beginning at the time of menses, an LHRH composition and sufficient levels of an estrogenic steriod to counteract the possibility of side effects which may develop during prolonged therapy with LHRH. Following the follicular phase, at the beginning of the luteal phase, and for the entire course of the luteal phase, the LHRH/estrogenic steroid combination administered during the follicular phase, in combination with a physiological amount of progestational steroid, is administered.
    Type: Grant
    Filed: August 9, 1989
    Date of Patent: July 14, 1992
    Assignee: The General Hospital Corporation
    Inventor: William F. Crowley, Jr.
  • Patent number: 5124167
    Abstract: Antioxidant compositions and methods are disclosed that are prepared by the extraction of natural antioxidants from plant substrates.
    Type: Grant
    Filed: July 25, 1990
    Date of Patent: June 23, 1992
    Assignee: Bar-Ilan University
    Inventors: Michael Albeck, Shlomo Grossman
  • Patent number: 5122598
    Abstract: New polysaccharide esters are disclosed, and more precisely esters of acidic polysaccharides chosen from the group formed by carboxymethylcellulose, carboxymethyl starch and carboxymethylchitin. These new esters and some esters of the type already known are useful as medicaments, for the manufacture of pharmaceutical and cosmetic preparations, in the field of biodegradable plastic materials and, therefore, for the manufacture of medical, surgical and sanitary articles, as well as numerous other industrial sectors in the place of acidic polysaccharides now in common use.
    Type: Grant
    Filed: May 12, 1989
    Date of Patent: June 16, 1992
    Assignee: Fidia S.p.A.
    Inventors: Francesco della Valle, Aurelio Romeo